Nucleic Acid Isolation and Purification Market by Product (Kits, Reagents, Instruments), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA), Application (Diagnostics, Personalized Medicine), End User (CROs), Region - Global Forecast to 2030

The nucleic acid isolation and purification market is expected to grow from USD 7.10 billion in 2025 to USD 10.99 billion in 2030, at a CAGR of 9.1% during the forecast period. PCR and other NAAT workflows are routine in many infectious disease programs. Labs are expanding test menus and handling higher sample volumes. NGS is also moving deeper into clinical use cases, increasing the need for clean DNA/RNA as a first step. Declining extraction quality affects downstream sensitivity. This encourages end users to continue investing in reliable NAIP workflows and reagents.

“The magnetic-bead based isolation and purification segment accounted for the largest share, by method, in the nucleic acid isolation and purification market in 2024.”

The nucleic acid isolation and purification market is segmented into magnetic bead-based isolation and purification, column-based isolation and purification, reagent-based isolation and purification, and other methods. In 2024, the magnetic bead-based isolation and purification method dominated the market. This dominance is driven by the compatibility of bead workflows with automation and high-throughput processing, which are priorities for hospitals, reference labs, and large research centers. Bead-based methods also deliver consistent yields and reproducibility across batches, helping labs reduce reruns and maintain turnaround times.

“The diagnostics segment was the largest application segment in the nucleic acid isolation and purification market in 2024.”

The nucleic acid isolation and purification market is segmented by application into diagnostics, drug discovery & development, personalized medicine, agriculture & animal research, and other applications. The diagnostics segment led the market in 2024. The primary reason is that DNA/RNA extraction is a necessary first step for most PCR/NAAT assays. In addition, a growing number of sequencing-based clinical tests is supporting expansion. High routine volumes from infectious disease panels, respiratory testing, and oncology molecular assays maintain steady demand. Diagnostic labs also prioritize standardized and validated workflows to reduce variability, avoid reruns, and shorten turnaround times.

“The Asia Pacific region will grow at the highest CAGR in the nucleic acid isolation and purification market from 2025 to 2030.”

The Asia Pacific region is estimated to be the fastest-growing segment of the market. This growth is supported by the expansion of population genomics programs and the rising focus on precision medicine. The region is also seeing increased demand for diagnosis and monitoring of rare and genetic diseases, especially in aging populations in markets such as Japan and China. As a result, sequencing and other molecular testing are being adopted more widely in routine healthcare.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1- 40%, Tier 2- 30% and Tier 3- 30%
• By Designation: Directors- 20%, Managers- 10% and Others - 70%,
• By Region: North America -35%, Europe -25%, Asia Pacific -25%, Latin America -10%, and Middle East -5%.

List of Companies Profiled in the Report:

• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• QIAGEN (Germany)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Promega Corporation (US)
• Agilent Technologies, Inc. (US)
• Danaher(US)
• Bio-Rad Laboratories, Inc. (US)
• Illumina, Inc. (US)
• Takara Bio Inc. (Japan)
• New England Biolabs (US)
• Abcam Plc (UK)
• KILPEST India Limited (India)
• Apical Scientific Sdn. Bhd. (Malaysia)
• Endress+Hauser Group Services AG (Switzerland)
• GENAXXON bioscience GmbH (Germany)
• LGC Biosearch Technologies (US)
• Zymo Research Corporation (US)
• Norgen Biotek Corp. (Canada)
• Omega Bio-Tek, Inc. (US)
• FAVORGEN Biotech Corp. (China)
• TIANGEN Biotech (Beijing) Co., Ltd. (China)
• AutoGen Inc. (US)
• PCR Biosystems (UK)
• Biogenuix (India)

Research Coverage

This research report categorizes the nucleic acid isolation and purification market by product [Kits, Reagents, Instruments (Manual, Automatic)], by type (Plasmid DNA isolation and purification, Total RNA isolation and purification, Genomic DNA isolation and purification, Messenger RNA isolation and purification, Circulating nucleic acid isolation and purification, MicroRNA isolation and purification, Other types), by method (Magnetic bead-based isolation and purification, Reagent-based isolation and purification, Column-based isolation and purification, Other methods), by application (Diagnostics, Drug discovery & development, Personalized medicine, Agriculture and animal research, Other applications), by end user (Hospitals and diagnostic centers, Academic and government research institutes, Pharmaceutical and biotechnology companies, Contract Research Organizations (CROs), Other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information on the major factors, such as drivers, challenges, opportunities, and restraints, that influence the growth of the nucleic acid isolation and purification market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, product portfolio, key strategies such as product launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the nucleic acid isolation and purification market. Competitive analysis of top players and upcoming startups in the nucleic acid isolation and purification market ecosystem is also covered in this report.

Key Benefits of Buying the Report

The report will help market leaders and new entrants by providing the closest approximations of revenue for the overall nucleic acid isolation and purification market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to better position their business and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following points:

Analysis of key drivers (routine PCR/qPCR and NGS testing scaling across care and research, expanding public health genomic surveillance in more countries), restraints (high cost and time required for high-volume testing), opportunities (automation impacting throughput, traceability, and staffing resilience, premium NAIP products for cfDNA, oncology, and low-input workflows), and challenges (variability due to PCR inhibitors and matrix effects) influencing the growth of the market.

• Product Development/Innovation: Detailed insights on newly launched products of the nucleic acid isolation and purification market
• Market Development: Comprehensive information about lucrative markets - the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the nucleic acid isolation and purification market
• Competitive Assessment: Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), QIAGEN (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Promega Corporation (US), Agilent Technologies, Inc. (US), Danaher(US), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), Takara Bio Inc. (Japan), New England Biolabs (US), Abcam Plc (UK), KILPEST India Limited (India), Apical Scientific Sdn. Bhd. (Malaysia), Endress+Hauser Group Services AG (Switzerland), GENAXXON bioscience GmbH (Germany), and LGC Biosearch Technologies (US), among others

Show more